Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patientsHIV 양성 환자에서 로수바스타틴 적정 단독요법과 비교한 에제티미브와 로수바스타틴 병용요법의 지질강하 효능 및 안전성Research Published on 2015-06-192022-09-06 Journal: Lipids in Health and Disease [Category] Communicable Disease, [키워드] addition AIP ALT Antiretroviral therapy API apoA1 ApoB Apolipoprotein B appear AST baseline characteristics C-reactive protein change Characteristics cholesterol clinical symptom Clinical symptoms clinical trial Combination combination treatment develop dose dyslipidemia dyslipidemias Efficacy Efficacy and safety eligible examined Ezetimibe group groups guideline HDL-C High-density lipoprotein High-density lipoprotein cholesterol High-sensitivity C-reactive protein HIV HIV-infected patient HIV-infected patients hsCRP improvement increase in LDL-C Lipid lipid profile Low-density lipoprotein Low-Density Lipoprotein cholesterol Mild minimum monotherapy myalgias not differ Open-label parameter Patient patients with HIV percentage plasma Primary outcome Randomized Result Rosuvastatin Safe Significant statin targets therapy Total cholesterol Transport treatment groups Trial Triglyceride two patients [DOI] 10.1186/s12944-015-0054-x PMC 바로가기 [Article Type] Research